ArticleBMJ open2025

Cost-effectiveness analysis of FOLFOXIRI/FOLFOXIRI and mFOLFOX6/FOLFIRI treatment in first-line and second-line chemotherapy for metastatic colorectal cancer.

Xianglian Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.